Instil Bio, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Instil Bio reported Q2 2026 cash, cash equivalents, restricted cash and marketable securities of $69.9M as of June 30, 2026 (down $6.4M from $76.3M at December 31, 2025), expecting this to fund operations beyond 2027. The company is actively evaluating acquisitions, in-licensing and related opportunities for novel therapeutics. Operating expenses declined significantly: R&D dropped to $0.3M and $0.9M for Q2 and H1 2026 respectively (vs. $6.7M and $12.1M in 2025), with net loss per share improving to $0.63 and $1.25 for Q2 and H1 2026 (vs. $3.24 and $7.55 in 2025).
Why this rating
Routine quarterly earnings disclosure. Cash burn slowed materially but runway remains finite; M&A pursuit is exploratory. No definitive transaction or guidance change disclosed. Relative to $83.4M market cap, modest cash position with declining burn rate suggests stabilization, not transformation.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.